Goldman Sachs’s CorMedix CRMD Stock Holding History

Goldman Sachs’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,320	Closed	-$10K	–	6785
2016 Q4	$10K	Sell	1,320 -1,600	-55%	-$16.2K	﹤0.01%	6760
2016 Q3	$37K	Buy	2,920 +1,860	+175%	+$17.4K	﹤0.01%	6568
2016 Q2	$11K	Buy	1,060 +80	+8%	+$1.22K	﹤0.01%	6843
2016 Q1	$13K	Buy	+980	New	+$9.51K	﹤0.01%	6845
2015 Q4	–	Sell	-1,900	Closed	-$19K	–	7170
2015 Q3	$19K	Sell	1,900 -20	-1%	-$308	﹤0.01%	7038
2015 Q2	$37K	Buy	+1,920	New	+$65.9K	﹤0.01%	6945

Other funds holding CRMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Goldman Sachs's CRMD Position: Q1 2026 in Review

Goldman Sachs reduced its CorMedix (CRMD) stake by 38% in Q1 2026, selling an estimated $2.35M and leaving 511,329 shares worth $3.47M. The position accounts for ﹤0.01% of the portfolio, ranked #4042.

Goldman Sachs first reported a position in CRMD in Q1 2014 and has held it in 33 quarters since. The position peaked at $9.64M in Q4 2025. 187 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

Goldman Sachs held 511,329 shares of CorMedix worth $3.47M as of Q1 2026.
Goldman Sachs sold 317,452 CorMedix shares in Q1 2026, an estimated $2.35M.
CorMedix made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4042 holding.
Goldman Sachs first reported a position in CorMedix in Q1 2014 and has held it in 33 quarters since.
Goldman Sachs's CorMedix position peaked at $9.64M in Q4 2025.
187 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.